Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 1,342

Document Document Title
WO/2008/125201A1
The present invention relates to polyurethane compositions which cure by radiation and thermal action with crosslinking, and use thereof for the production of holographic media. The polyurethane compositions of the invention comprise A) ...  
WO/2008/116302A1
The present invention relates to novel compounds of the formula (I), wherein R'-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of ca...  
WO/2008/110583A1
The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, whe...  
WO/2008/009750A3
The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments...  
WO/2007/145835A3
Benzamide derivatives of formula ( I ) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders, formula (I), wherein R1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, and n...  
WO/2007/016095A3
The invention describes compositions and kits comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and novel compositions...  
WO/2008/009750A2
The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments...  
WO/2007/145835A2
Benzamide derivatives of formula ( I ) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders, formula (I), wherein R1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, and n...  
WO/2002/068586A3
With the help of X-ray structural analyses of drug-resistant HIV proteases and molecular modeling, a new type of inhibitor with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant muta...  
WO/2007/074169A3
The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.  
WO/2007/104135A1
A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above ...  
WO/2007/102590A1
Disclosed is an optically active compound represented by the general formula (I): (I) wherein X1, X2, X3 and X4 independently represent -NH2, -N(CH3)2, -H, -CpF2p+1, -SCqH2q+1, -CrH2r+1, -OCsH2s+1, -F, -I, -Br, -Cl, -COOH, -COOCtH2t+1, -...  
WO/2007/079869A2
The invention relates to cyclic aminals, obtained from fragrance aldehydes or biocidal aldehydes, suitable for example for perfuming or conserving washing and cleaning agents and the materials treated with the washing and cleaning agents...  
WO/2007/074171A1
Methods for the synthesis of various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds (I) and their pharmaceutically acceptable salt derivatives are provided. The compounds of the invention are claimed and a...  
WO/2007/074169A2
The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.  
WO/2007/039463A1
The present invention provides compounds of formula (I) where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further prov...  
WO/2007/031213A1
Novel dioxazine- and oxadiazine-substituted arylamides of the formula (I) in which A1, A2, R1, R2, R3, R4 and R5 are as defined in the description, a plurality of processes for preparing these compounds and their use for controlling pest...  
WO/2007/012464A1
The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and...  
WO/2006/065277A3
Disclosed are compounds of the formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, and pharmaceutical compositions comprising the compounds of formula (I). Also disclosed is the method of inhi...  
WO/2007/000098A1
The invention, discloses substituted p-trifluoromethyl phenylethers of formula (I), the preparation and the use thereof, wherein each substituent is defined as in the description. The compounds of the invention have broad spectrum activi...  
WO/2006/127364A1
Compounds of formula (I), in which B1 and X1 are together alkylene which is unsubstituted or substituted with =O and having one CH2 moiety unreplaced or replaced with CH=CH, O, NH or N(alkyl), which inhibit the activity of antiapoptotic ...  
WO2005041899A3
The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structur...  
WO2005103041A3
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...  
WO2006074940A3
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...  
WO2006061417A3
The present invention concerns kinase inhibitors formula, formula (I), the N-oxide forms, the pharmaceutically isomeric forms thereof, wherein Z represents NH and the other substituents are defined as in the claims.  
WO/2006/074950A1
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base fo...  
WO/2006/074501A1
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in...  
WO/2006/074940A2
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...  
WO/2006/065277A2
Disclosed are compounds of the formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, and pharmaceutical compositions comprising the compounds of formula (I). Also disclosed is the method of inhi...  
WO/2006/061415A1
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z1 and Z2 represent NH; Y represents -C3-9alkyl-, -C3...  
WO/2006/061417A2
The present invention concerns kinase inhibitors formula, formula (I), the N-oxide forms, the pharmaceutically isomeric forms thereof, wherein Z represents NH and the other substituents are defined as in the claims.  
WO2005107464A3
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.  
WO/2006/045587A1
A process for the preparation of [1,4,5]-oxidiazepine derivatives by reaction of 4,5-diacyl-[1,4,5]-oxidiazepines with a base.  
WO/2006/040002A1
The invention relates to novel 1,3,4-oxadiazine-5-on derivatives of general formula (I), methods for the production thereof, the use thereof for treating and/or preventing diseases, and the use thereof for producing medicaments used for ...  
WO2006016167A3
The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in. one aspect the present invention provides 17-desmethylrapamycin and analogu...  
WO/2006/026531A1
An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creati...  
WO2005113542A3
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R
WO/2006/021368A1
The invention relates to a novel method for producing 3-(1-hydroxyphenyl-1-alkoximinomethyl)dioxazines of formula (I), and to a device for carrying out this method.  
WO/2006/011466A1
Disclosed are a compound and pharmaceutically acceptable salts thereof represented by the general formula (1) below. (In the formula (1), R1, R2, R3, R4 and X are the same as R1, R2, R3, R4 and X defined in the description.)  
WO2005103041A9
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...  
WO/2005/113542A2
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as...  
WO/2005/107464A2
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.  
WO2005016874A3
The invention describes crown ether chelators, including crown ethers having the formula (A) or (B); and aza-substituted and thia-substituted analogs thereof. These crown ethers may be substituted by a dye moiety, a chemically reactive g...  
WO/2005/103019A1
Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 a...  
WO/2005/103041A2
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...  
WO2005055715A3
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, R, R, R, R, b, c, R, R, R, R, R<5>, d, e, U, V, X...  
WO/2005/090292A1
The invention relates to a compound having general formula (I), wherein: A is selected from among one or more X, Y and/or Z groups; X represents an optionally-substituted methylene group; Y represents a C2-alkenylene, optionally substitu...  
WO2005068445A3
The invention relates to compounds of formula (I) wherein Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or taut...  
WO/2005/087236A1
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.  
WO/2005/082870A1
It is intended to provide an ABC transporter inhibitor whereby the multi-drug resistance against anticancer drugs caused by the amplification and expression of MDR1 gene, which is the most serious problem in chemotherapy for cancer, or t...  

Matches 101 - 150 out of 1,342